Investigating the Heterogeneity of Treatment Effect of Antifibrotic Agents in Patients with Interstitial Lung Disease

Interstitial lung diseases (ILDs) are a group of conditions that cause scarring (also called fibrosis) in the lungs. This scarring makes it difficult for the lungs to work properly, leading to shortness of breath and reduced quality of life. One of the most serious forms is idiopathic pulmonary fibrosis (IPF), which gets worse over time and can be life-threatening. Together, these diseases affect thousands of people every year across the world.

There are medications called antifibrotic drugs—such as pirfenidone and nintedanib—that can help slow down the progression of lung scarring. Pirfenidone helps reduce inflammation and prevents scar tissue from forming. Nintedanib blocks certain proteins involved in the development of scar tissue. While these treatments do not cure the disease, they can slow its progression and help people maintain lung function for longer. However, not everyone responds to antifibrotic drugs in the same way. Some people benefit a lot, while others see little or no improvement. Currently, doctors have no reliable way to predict how well a patient will respond to these treatments. This research aims to understand why that is and to find out which patients are most likely to benefit.

To do this, researchers will analyze data from several previous clinical trials that studied antifibrotic drugs in people with ILD. By combining data from different trials, the researchers can study a wide range of patients and look for meaningful patterns.
The team will use advanced data analysis tools, including machine learning (a type of computer modeling), to study individual differences in treatment response. They will look for groups of patients who respond better—or worse—to antifibrotic therapy and try to understand what features those patients share.

This research will help doctors better match patients with the treatments that are most likely to work for them. It could also help future research into new therapies and tests that predict treatment response, bringing us closer to more personalized and effective care for people with interstitial lung disease.